BioMarin Pharmaceutical Inc. (BMRN) Seen as Attractive Buy Ahead of Transcon-CNP PDUFA, Says Wells Fargo

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the 20 Best Investments in 2026. BioMarin Pharmaceutical Inc. (BMRN) Seen as Attractive Buy Ahead of Transcon-CNP PDUFA, Says Wells Fargo BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is next on our list. TheFly reported on February 18 that Wells Fargo & Company increased its price target for BMRN from $70 to $75 while keeping an Overweight rating. The firm believes the upcoming Transcon-CNP PDUFA may mark the final negative catalyst for BMRN, and its sum ...